Current status of transarterial chemoembolization (TACE) agents in hepatocellular carcinoma treatment

被引：11

作者：

Larijani, Roshana Saghafian ^{[1
]}

Ravari, Nazanin Shabani ^{[1
]}

Goodarzi, Navid ^{[2
]}

Akhlaghpour, Shahram ^{[3
]}

Larijani, Samaneh Saghafian ^{[4
]}

Rouini, Mohammad Reza ^{[5
]}

Dinarvand, Rassoul ^{[1
,2
]}

机构：

[1] Univ Tehran Med Sci, Fac Pharm, Dept Pharmaceut, Tehran, Iran

[2] Univ Tehran Med Sci, Fac Pharm, Nanotechnol Res Ctr, 1417614315, Tehran, Iran

[3] Pardis Noor Med Imaging Ctr, Tehran, Iran

[4] Iran Univ Med Sci, Res & Clin Dev Ctr, Firoozabadi Hosp, Tehran, Iran

[5] Univ Tehran Med Sci, Fac Pharm, Dept Pharmaceut, Biopharmaceut & Pharmacokinet Div, Tehran, Iran

来源：

JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY | 2022年 / 77卷

关键词：

Chemoembolization; Embolization; Hepatocellular carcinoma; Microsphere; Radiopaque microsphere; DEGRADABLE STARCH MICROSPHERES; ATEZOLIZUMAB PLUS BEVACIZUMAB; RANDOMIZED CONTROLLED-TRIAL; DOXORUBICIN-ELUTING BEADS; FATTY LIVER-DISEASE; IN-VITRO; LIPIODOL CHEMOEMBOLIZATION; RADIOFREQUENCY ABLATION; ARTERIAL EMBOLIZATION; MULTIDRUG-RESISTANCE;

D O I：

10.1016/j.jddst.2022.103905

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Primary liver cancer is among the most common fatal solid cancers, ranking as the fourth most frequent cause of cancer-related mortality worldwide. Hepatocellular carcinoma (HCC) is the most prevalent histological type of primary liver cancers, which accounts for up to 90% of cases and is resistant to a large percentage of currently available anti-cancer drugs. Amongst various therapeutic options, transarterial chemoembolization (TACE) is an efficient option in patients with the intermediate stage of HCC. Commercially, different embolients enable cli-nicians to perform TACE. Embolic materials include gelatin sponge, degradable starch microspheres (DSMs) and calibrated microspheres. This article reviews commercially available materials used in the TACE procedure and evaluates their pros and cons in this regard.

引用

页数：13

共 182 条

[1] Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma [J].

Abou-Alfa, G. K. ;

Meyer, T. ;

Cheng, A. -L. ;

El-Khoueiry, A. B. ;

Rimassa, L. ;

Ryoo, B. -Y. ;

Cicin, I. ;

Merle, P. ;

Chen, Y. H. ;

Park, J. -W. ;

Blanc, J. -F. ;

Bolondi, L. ;

Klumpen, H. -J. ;

Chan, S. L. ;

Zagonel, V. ;

Pressiani, T. ;

Ryu, M. -H. ;

Venook, A. P. ;

Hessel, C. ;

Borgman-Hagey, A. E. ;

Schwab, G. ;

Kelley, R. K. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (01) :54-63

[2] Principles of and Advances in Percutaneous Ablation [J].

Ahmed, Muneeb ;

Brace, Christopher L. ;

Lee, Fred T., Jr. ;

Goldberg, S. Nahum .

RADIOLOGY, 2011, 258 (02) :351-369

[3]

Ajita Deodhar J.K., 2014, EMBOLIZATION THERAPY

[4]

Akhlaghpour S., 2006, J RADIOL, V3, P147

[5]

[Anonymous], CE MARK APPROVAL TRA

[6]

[Anonymous], EMBOCUBE EMBOLIZATIO

[7]

[Anonymous], DC BEAD LUMITMRADIO

[8]

[Anonymous], BIOPEARLTM 1 BIODEGR

[9]

[Anonymous], BEARING NSPVA EMBOLI

[10]

[Anonymous], PVA FOAM EMBOLIZATIO

← 1 2 3 4 5 6 7 8 9 10 →